

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
 International Bureau



(43) International Publication Date
 24 July 2003 (24.07.2003)

PCT

(10) International Publication Number
 WO 03/059388 A1

- (51) International Patent Classification⁷: A61K 47/02, A61P 9/14
- (21) International Application Number: PCT/IS03/00002
- (22) International Filing Date: 14 January 2003 (14.01.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
 6233 15 January 2002 (15.01.2002) IS
- (71) Applicant (for all designated States except US): DELTA HF. [IS/IS]; Reykjavikurvegi 78, IS-220 Hafnarfjörður (IS).
- (72) Inventor; and
- (75) Inventor/Applicant (for US only): EYJOLFSSON, Reynir [IS/IS]; Eyrarholti 6, IS-220 Hafnarfjörður (IS).
- (74) Agent: A & P ARNASON; Efstaleiti 5, IS-103 Reykjavík (IS).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Declaration under Rule 4.17:**
 — of inventorship (Rule 4.17(iv)) for US only
- Published:**
 — with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

(54) Title: FORMULATIONS OF QUINAPRIL AND RELATED ACE INHIBITORS

(57) Abstract: Stable formulations of ACE-inhibitors compounds such as quinapril can be produced with the use of excipients comprising a basic compound, preferably an alkali-oralkaline earth metal carbonate, and an insoluble alkaline-earth metal carbonate, and an insoluble alkaline-earth metal hydrogen phosphate. Tablets of such formulations have good storage stability, dissolution characteristics, and the formulations are suitable for use in drug combinations.



WO 03/059388 A1